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ABSTRACT 
Blood-brain barrier (BBB) dysfunction complicates CNS lupus, an important aspect of 
systemic lupus erythematosus. To gain insight into the underlying mechanism, vascular 
corrosion casts of brain were generated from the lupus mouse model, MRL/lpr mice and the 
MRL/MPJ congenic controls. Scanning electron microscopy of the casts showed loss of 
vascular endothelial cells in lupus mice compared to controls. Immunostaining revealed 
significant increase in caspase-3 expression in the brain vascular endothelial cells, which 
suggest that apoptosis could be an important mechanism causing cell loss, and thereby loss of 
BBB integrity. Complement activation occurs in lupus resulting in increased generation of 
circulating C5a, which caused the endothelial layer to become ‘leaky’. In this study, we show 
that C5a and lupus serum induced apoptosis in cultured human brain microvascular 
endothelial cells (HBMVEC), while selective C5a receptor 1 (C5aR1) antagonist reduced 
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apoptosis in these cells, demonstrating C5a/C5aR1-dependence. Gene expression of initiator 
caspases, caspase 1 and caspase 8, and proapoptotic proteins DAPK1, FADD, Cell death-
inducing DFFA-like effector B (CIDEB) and BAX were increased in HBMVEC cells treated 
with lupus serum or C5a, indicating that both the intrinsic and extrinsic apoptotic pathways 
could be critical mediators of brain endothelial cell apoptosis in this setting. Overall, our 
findings suggest that C5a/C5aR1 signaling induces apoptosis via activation of FADD, 
caspase 8/3 and CIDEB in brain endothelial cells in lupus. Further elucidation of the 
underlying apoptotic mechanisms mediating the reduced endothelial cell number is important 
in establishing potential therapeutic effectiveness of C5aR1 inhibition that could prevent 
and/or reduce BBB alterations and preserve its physiological function in CNS lupus. 
 
 
SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) is a devastating autoimmune disease that is 
multifactorial and leads to multiorgan failure (1-3). 40-70% of SLE patients are affected with 
central nervous system (CNS) lupus, yet the exact mechanism causing the pathology remains 
unknown. The CNS is uniquely positioned and protected from the circulatory system by the 
blood-brain barrier (BBB) (4) . The BBB is formed by the endothelial cells surrounded and 
supported by the astroglial cells and the astrocytic endfeet. The BBB is crucial since it 
maintains the brain internal milieu constant allowing optimal neuronal function. Loss of BBB 
integrity could lead to influx of inflammatory cells, and molecules such as autoantibodies 
causing brain injury. Our earlier studies using the well-established lupus mouse model 
MRL/lpr mice revealed that the BBB integrity is lost with worsening disease (5, 6). 
MRL/lpr mice is a well-established mouse model for human lupus thought to accurately 
reflect pathologic events that occur in human SLE, including CNS lupus (7-10). MRL/lpr 
mice differ from the congenic MRL/MpJ (MRL+/+) strain by the absence of the proapoptotic 
membrane Fas protein, due to a retroviral insertion in the Tnfrsf6 gene (11-13). Using these 
mice, our studies also show that the loss of BBB integrity is complement dependent (5, 6, 
14). The complement (C) cascade is as a protective mechanism in host defense. However, in 
autoimmune diseases such as SLE, when the complement system is excessively and 
chronically activated, the beneficial effects can become detrimental to the host (15-17).  
The complement system contains three major initiation pathways and over 40 proteins (18-
20). Our studies showed for the first time that apoptosis occurred in experimental lupus 
brains, which was complement-dependent (21). Complement activation results in the 
generation of anaphylatoxins, C3a and C5a (22, 23). Subsequent studies from our lab showed 
that C5a/C5aR signaling aggravated CNS lupus. C5a caused neuronal cells in culture to 
become apoptotic (24). C5a binds to two receptors, the G-coupled, C5aR1 and the alternate 
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receptor, C5aR2 (25-27). C5a/C5aR1 signaling mediates a number of biological processes, 
including chemotaxis and degranulation of mast cells, basophils, neutrophils, and eosinophils, 
increasing vascular permeability, an increased generation of reactive oxygen species, and 
production of cytokines from monocytes and macrophages (28). Interestingly, C5a/C5aR 
signaling can be either protective or neurotoxic (29) depending on the setting, however 
increases in circulating C5a correlate with poor outcomes in SLE (30, 31). C5a can contribute 
to cellular apoptosis in conditions such as lupus (24) and stroke (32), or may have an anti-
apoptotic effect on neutrophils, during sepsis (33, 34). C5aR1 is present predominantly on 
blood myeloid cells, but is also constitutively expressed on several cell types in the brain 
including endothelial cells (35, 36). Using cultured brain endothelial cells, this study assessed 
the role of C5a/C5aR signaling in rendering endothelial cells apoptotic. 
Apoptosis is regulated by the sequential activation of initiator and effector caspases (37). The 
autocatalytic activation of an initiator caspase depends on multiprotein complexes which are 
comprise of different factors such as apoptotic protease-activating factor 1 (Apaf-1) and 
cytochrome c (CytC) (38, 39). One of the key adaptor proteins transmitting apoptotic signals 
is Fas-associated protein (FADD) (40, 41). FADD activation can follow a more than one 
pathway: it can bind to FAS and procaspase 8 forming the death-inducing signaling complex 
(DISC) (42-45), which then cleaves and activates caspase-3, -6 and -7.  Alternatively, FADD 
can recruit the initiator caspase, procaspase-10 and the caspase-8/10 regulator c-FLIP 
(FADD-like interleukin-1β–converting enzyme (FLICE)-inhibitory protein) (41, 46, 47). An 
additional apoptotic pathway includes CIDEB, a member of the CIDE (cell death-inducing 
DFF45 [DNA fragmentation factor 45]-like effector) family of apoptosis-inducing factors 
(48, 49), was found to be upregulated in the spinal cord consistent with neuronal apoptosis 
after nerve injury. The N-terminal region of CIDEs is homologous to the CIDE-N domains in 
DFF40/CAD (caspase-activated nuclease) and its inhibitor (DFF45/ICAD [inhibitor of 
CAD]), which are 2 subunits of the DFF complex (50-52). Cleavage of DFF45/ICAD by 
caspase 3 releases DFF40/CAD from the complex, which leads to DNA fragmentation and 
nuclear condensation.  
 To understand the changes that occur in the brain vasculature in lupus, this study addressed 
two facets: Firstly, vascular remodeling and endothelial cell alteration in brains of lupus 
mice, and secondly, the role of the complement protein C5a and apoptosis in human brain 
endothelial cells in lupus. Our studies demonstrate for the first time that vascular changes 
occur in lupus brain with endothelial cell loss. One of the mechanisms that could be causing 
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the cell loss was apoptosis, which occurred when HBMVEC were treated with lupus serum or 
C5a indicating the translational potential of these studies. 
 
MATERIALS AND METHODS 
Experimental protocol in lupus mice 
MRL/lpr and MRL+/+ mice (n=4 in each group) were purchased from The Jackson 
Laboratory (Bar Harbor, ME, USA), and maintained in the facility with free access to food 
and water. They were used for experiment at 18 weeks of age. These studies were approved 
by the University at Buffalo Animal Care and Use Committee.  
Vascular Corrosion Casting 
Vascular corrosion casting of the brain vasculature was performed on all animals 
immediately after euthanasia using Batson's No. 17 Corrosion Casting Kit (Polysciences, 
Inc., Warrington, PA, USA), as described previously (53, 54). In brief, anesthesia was 
induced using 2-3% isoflurane and mice were euthanized using 4% isoflurane. Immediately 
thereafter, mice were perfused with 5 ml sterile saline injected through an 18G winged needle 
inserted into the left ventricle. After perfusion, approximately 4 mL of Batson's No. 17 
Corrosion Cast mixture was injected via the left ventricle. After injection of the casting 
mixture, whole specimens were kept at 4°C overnight to allow for complete polymerization 
of the casting mixture. The brain was then extracted and placed in 20% potassium hydroxide 
for 2 days on a rocking platform. Once the brain tissue dissolved, the vascular corrosion cast 
was isolated and rinsed with distilled water. 
Scanning Electron Microscopy Imaging  
Scanning electron microscopy was used to investigate the morphologic features of the 
vascular casts, specifically imprints of endothelial cells, as described earlier (53, 55-57). Prior 
to imaging, perforating arteries were eliminated from the major vessels Circle of Willis. The 
casts were affixed to a metal stand with clay, coupled to the stand with graphite paint, and 
scatter coated with carbon under vacuum. Vascular casts of the mouse Circle of Willis were 
imaged at 50 x with a Hitachi SU-70 scanning electron microscope (Hitachi High 
Technologies America, Inc., Roslyn Heights, NY, USA). Areas along major vessels of the 
Circle of Wills were imaged at higher magnification (300-600 x).  
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Quantification of Endothelial Cell Density in the Cerebral Vasculature 
High magnification SEM images of the major cerebral vessels were used to quantify 
endothelial cell density in lupus and control mice. For each mouse, three 50 µm by 50 µm 
(2,500 µm2) representative interrogation windows were created on SEM images of major 
Circle of Willis vessels using Image J software.. The number of endothelial cell imprints in 
each window was then counted and averaged for each mouse. The average cell density of the 
lupus mice were compared against that of control mice by a Student’s t-test (significance at 
p<0.05).   
Immunofluorescence staining of MRL/lpr and MRL+/+ mice brain section. 
At 18 wk of age, the MRL/lpr and MRL+/+ mice were sacrificed and the brains were 
harvested. These studies were approved by the University of Buffalo Animal Care and Use 
Committee. Cerebral cortexes were snap-frozen in Tissue-Tek O.C.T. (optimal cutting 
temperature) compound (Ted Pella, Redding, CA, USA), placed in precooled 2-
methylbutane, and stored at −80°C until use. Cryosections (7 μm) were fixed using 4% 
paraformaldehyde for 15 minutes followed by 1% triton for 5 min. Standard 
immunofluoresecent staining procedures were followed. Briefly, Sections were stained using 
Alexa 488 labelled agglutinin1 (1:100, Vector Labs) and rabbit anti-mouse caspase 3 (1:50, 
Santa Cruz Biotechnology) followed by Alexa 594 labeled anti-rabbit antibody. Sections 
were observed and photographed with a Zeiss microscope (Carl Zeiss, Oberkochen, 
Germany). The Caspase-3 expression levels were quantitated based on the intensity of the 
fluorescent signal analyzed using the computer image analysis image J software (National 
Institutes of Health, Bethesda, MA, USA).   
Cells in culture 
To determine whether endothelial cell apoptosis was a key event during loss of BBB integrity 
in lupus we used HBMVECs (Cat# ACBRI-376) (58-60). These primary Human Brain 
microvascular cells were obtained from Applied Cell Biology Research Institute (ACBRI, 
Kirkland, WA). HBMVECs were seeded on 1% gelatin-coated 25-cm2 tissue-culture flasks 
and grown in CS-C complete medium (ABCRI) supplemented with 10% fetal bovine serum 
Gibco- Life technologies, Grand Island, NY, USA, heparin (100 lg/ml), endothelial cell 
growth factor supplement (50 lg/ml), sodium pyruvate (2 mM), L-glutamine (2 mM), 
penicillin (100 U/ml) and streptomycin (100 lg/ml) (Sigma-Aldrich, St Loius, MO, USA) 
with attachment factors (ABCRI) at 37°C in a humidified 5% CO2 incubator. Cultured cells 
were identified as endothelial by their morphology and von Willebrand factor antibody and 
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their viability assessed by MTT assay. HBMVEC are obtained at passage 2 for each 
experiment and are used for all experimental paradigms between 2-8 passages, within 6 to 27 
cumulative population doublings. We observed greater than 98% viability for HBMVECs in 
culture. 
Treatment of cells 
HBMVEC were treated with serum isolated from control patients or lupus patients (5%), 
10nM human C5a (R & D Systems, Minneapolis, MN, USA) or the selective C5aR1 
antagonist (C5aRa, 0.1μg/ml) PMX53 (61). The concentrations of lupus serum, C5a, and 
C5aRa were based on the response obtained in our previous studies (62). Clinical samples 
were obtained from children attending the pediatric rheumatology clinics at the Women and 
Children's Hospital of Buffalo.  Samples were obtained from 2 boys and 6 girls who ranged 
in age from 7 to 15 years.  The serum samples were obtained from newly diagnosed patients 
during a clinical visit. The C3/C4 levels were below normal (C3: 80-175 mg/dl; C4: 14-40 
mg/dl) indicating complement activation. Approval to acquire and use clinical materials was 
in accordance of University at Buffalo Children and youth IRB. 
Cell viability using the MTT Assay  
Viability of HBMVEC in culture prior to and after treatment with lupus serum, C5a and 
C5aRa was assessed using the MTT assay. The assay measures the ability of an active 
mitochondrial enzyme to reduce the MTT substrate (yellow to blue) in live cells. Isolated 
cells were plated in serum-free conditions on 48-well plates pre-coated with laminin. After 24 
h of culture, 0.5 mg/ml MTT substrate (Thiazolyl Blue Tertrazolium Bromide) was added 
and cells were incubated for additional 4 h, and then solubilized with 10% SDS/HCl (0.01N) 
overnight. Absorbance was measured at 595 nm.   
Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling assay 
Terminal deoxynucleotidyl transferase-mediated dUTP end labeling (TUNEL) assay was 
performed as described earlier (21, 63, 64) to visualize DNA damage in cells. 1×104 cells 
were seeded into the 35 mm culture dishes with glass bottom wells. Next day, the media were 
exchanged for fresh RPMI-1640 medium. The cells were treated with lupus serum, C5a or 
lupus serum+C5aRa for 48 hrs. Respective negative control also maintained without 
treatment. Cells were fixed with 4% methanol-free paraformaldehyde in PBS for 10 min at 
room temperature. After fixation, wells were washed with PBS, permeabilized with a 0.2% 
Triton X-100 solution for 5 min, and washed twice in phosphate-buffered saline, then 100 μL 
of equilibration buffer was added at room temperature and incubated for 5–10 min. Samples 
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were washed with PBS and incubated with terminal deoxynucleotidyl transferase, 
recombinant (rTdT) buffer at 37°C for 60 min inside the humidified chamber according to the 
manufacturer’s protocol (Biotool.com; CAT #B31115 TUNEL Apo-Green Detection Kit). 
Reaction was terminated by adding 100 μL of SSC for 15 min. The wells were washed thrice, 
using PBS for 5 min to remove unincorporated fluorescein-12-dUTP nucleotides. Fragmented 
DNA was examined under inverted fluorescence microscope (Carl Zeiss). For each sample, 
the total number of cells and the number of TUNEL-positive cells were quantified in 10 
representative fields. The results were presented as a representation from a series of three 
separate experiments. 
CellEvent® Caspase-3/7 Apoptosis Detection Reagent 
HBMVEC are grown to 70% confluence in a petri dish with a glass bottom and treated with 
lupus serum, C5a or lupus serum+C5aRa for 48 hrs. After incubation, cells are wash in PBS 
followed by addition of the   CellEvent® Caspase-3/7 Green Detection Reagent which allow 
examination of caspase-3/7 activation in live cells. The CellEvent® Caspase-3/7 Green 
Detection Reagent constitutes a intrinsically non-fluorescent four amino acid peptide called 
DEVD peptide that inhibits the ability of the dye to bind to DNA. However, after activation 
of caspase-3/7 in apoptotic cells, the DEVD peptide is cleaved enabling the dye to bind to 
DNA and produce a bright, fluorogenic response. The fluorescence emission of the dye when 
bound to DNA is ~530 nm and can be observed in the FITC range. 
RNA extraction  
Cytoplasmic RNA was extracted by an acid guanidinium-thiocyanate-phenol-chloroform 
method as described using Trizol reagent (Invitrogen- Life Technologies, Carlsbad, CA). The 
amount of RNA was quantitated using a Nano-Drop ND-1000 spectrophotometer (Nano-
Drop™, Wilmington, DE) and isolated RNA is stored at –80oC until used.  
qPCR analysis of apoptosis responsive genes 
Apoptosis related genes expression was analyzed with quantitative reverse transcription-PCR 
(RT-PCR; Applied Biosystems 7500 Fast, Foster City, CA) using a real-time SYBR 
Green/ROX gene expression assay kit (QIAGEN). cDNA was directly prepared from 
cultured cells using a Fastlane® Cell cDNA kit (QIAGEN, Germany); and mRNA levels of 
apoptotic genes such as, Bax, FADD and caspase 1,4,8 and 10 as well as the reference gene, 
β-actin, were analyzed using gene-specific SYBR Green-based QuantiTect® Primer assays 
(QIAGEN, Germany). qPCR was performed in a reaction volume of 25 μL according to the 
manufacturer’s instructions. Briefly, 12.5 μL of master mix, 2.5 μL of assay primers (10×) 
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and 10 μL of template cDNA (100 ng) were added to each well. After a brief centrifugation, 
PCR plate was subjected to 35 cycles under the following conditions: (i) PCR activation at 
95°C for 5 minutes, (ii) denaturation at 95°C for 5 seconds and (iii) annealing/extension at 
60°C for 10 seconds. All samples and controls were run in triplicate on a Stratagene 
MX3000P Real-Time PCR system. To provide precise quantification of the initial target in 
each PCR reaction, the amplification plot is examined and the data are calculated as 
described. Relative expression of mRNA species was calculated using the comparative 
threshold cycle number (CT) method (65). Briefly, for each sample, a difference in CT values 
(∆CT) is calculated for each mRNA by taking the mean CT of duplicate tubes and subtracting 
the mean CT of the duplicate tubes for the reference RNA (-actin) measured on an aliquot 
from the same RT reaction. The ∆CT for the treated sample is then subtracted from the ∆CT 
for the untreated control sample to generate a ∆∆CT. The mean of these ∆∆CT measurements 
is then used to calculate the levels in the targeted cytoplasmic RNA relative to the reference 
gene and normalized to the control as follows: Relative levels or Transcript Accumulation 
Index = 2-∆∆CT. This calculation assumes that all PCR reactions are working with 100% 
efficiency. All PCR efficiencies were found to be >95%; therefore, this assumption 
introduces minimal error into the calculations. All data were controlled for quantity of RNA 
input and by performing measurements on an endogenous reference gene, β-actin.  
Statistical Analysis: 
Data are expressed as Means ± SE and were analyzed using Minitab 12 statistical software 
(Minitab, State College, PA, USA). For comparisons between 2 groups, “t-test”was used for 
parametric data and Mann-Whitney test for nonparametric data. Statistical comparisons 
between more than 2 groups was done using an analysis of variance (ANOVA). A post hoc 
analysis using Bonferroni’s test was done. A statistical significant difference was accepted 
when p value was < 0.05 
 
RESULTS 
 
Vascular pathologic changes in lupus brain 
We measured endothelial cell density in the cerebral vasculature on vascular corrosion casts 
of the Circle of Willis of lupus and control mice. In both groups, endothelial cells aligned 
with the direction of blood flow through the vessels. Quantification of endothelial cell 
number on high magnification SEM images of the casts demonstrated that lupus brain vessels 
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had significantly lower cell density (3.23x103 cells/mm2) than vessels from congenic controls 
(5.07x103 cells/mm2, p=0.016)  (Figure 1).  
 
Apoptosis leads to loss of endothelial cells in brain vasculature.  
To determine whether the effect of reduced number of endothelial cells observed in the casts 
from MRL/lpr mice could be due to apoptosis, brain sections were stained for Caspase 3 
using Alexa 488 labelled isolectin and rabbit anti-mouse caspase 3 followed by Alexa 594 
labeled anti-rabbit antibody. Sections were observed and photographed with a Zeiss 
microscope (Carl Zeiss, Oberkochen, Germany).  Isolectin staining overlaid with caspase-3 
staining demonstrates that the walls of the microvessels in MRL/lpr mouse underwent 
caspase-dependent apoptosis, which could alter the integrity of the brain microvasculature. 
(Figure 2). 
C5a reduces cell viability in brain endothelial cells in lupus.  
Viability of HBMVECs in culture prior to and after treatment with lupus serum, C5a and a 
C5aR1 antagonist (C5aRa) was assessed using the MTT assay. A significant decrease in cell 
viability was observed in HBMVEC cells post treatment with lupus serum as compared to the 
cells treated with normal serum (Figure 3). To determine the mechanism/s by which the cell 
number is reduced, apoptosis was assessed in HBMVEC treated with lupus serum and C5a. 
Apoptosis was determined by 2 independent methods: anti-active caspase 3 assay and 
TUNEL. 
C5a induces caspase activation in lupus serum treated endothelial cells  
Caspase-3/7 activation was significantly increased in C5a and lupus serum treated cells as 
compared to the normal serum treated HBMVEC controls (Figure 4). Image J quantitation of 
fluorescence signal intensity in pixel units indicates a significant increase in the fluorescence 
signal in C5a treated (46% increase, p<0.05) and lupus treated (65% increase, p<0.01) 
BMVEC cells as compared to the normal controls. Treatment of HBMVEC with the C5aRa 
and subsequently with lupus serum, resulted in  significantly decrease  in activation of 
caspase-3/7 as indicated by  lesser  fluorescence signal intensity as compared to HBMVEC 
treated with lupus  serum alone  (57% decrease p<0.05) indicative of the involvement of 
C5a/C5aR1 signaling in lupus. 
DNA damage induced by lupus serum is C5a dependent 
DNA damage was analyzed using TUNNEL assay. TUNEL assay confirmed the presence of 
terminal DNA damage in lupus serum treated cells compared to HBMVEC cells treated with 
normal serum (Figure 5).  Increased APO-green florescence intensity indicates the degree of 
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DNA damage induced by lupus serum or C5a. Significant increase in APO-green 
fluorescence intensity in C5a and lupus serum treated cell was observed as compared to the 
normal serum treated HBMVEC controls. Image J quantitation of fluorescence signal 
intensity in pixel units indicates an increase in the fluorescence signal in C5a treated (31% 
increase, p<0.05) and lupus treated (61% increase, p<0.01). HBMVEC cells as compared to 
the normal controls. Treatment of HBMVEC with the C5aRa and subsequently with lupus 
serum, resulted in significantly decrease in APO-green fluorescence intensity as compared to 
BMVEC treated with lupus serum alone (45% decrease p<0.05). The results confirm lupus 
serum treated cells undergo cell death by apoptosis and that complement involvement via 
C5a/C5aR1 signaling is likely to be mechanism via which endothelial cell death and BBB 
breakdown occurs in lupus associated neurodegeneration.   
Apoptotic gene expression profiling using quantitative PCR 
Changes in apoptotic gene expression levels was analyzed in endothelial cells treated with 
lupus serum or C5a by real-time PCR. An array of apoptotic genes were evaluated, selected 
based on their role in the intrinsic and extrinsic apoptotic pathways. Therefore, the effect of 
C5a/C5aR1 signaling on the  gene expression of BCL2 11 BAX, BIK, APAF-1, CASP1, 
CASP4, CASP8, CASP10, CIDEB, FADD, DAPK1 and DFFA genes were examined in 
HBMVEC treated with lupus serum for 24 h, C5a or the C5aRa. mRNA was extracted and 
subjected to qRT-PCR using specific primers. Table 1 provides the list of primers used as 
well as the PCR conditions. We observed a significant increase in gene expression levels of 
pro-apoptotic genes such as BAX (123%, p<0.001); BCL-2L11 (82%, p<0.01); BIK (41%, 
p<0.05) and APAF-1 (34%, p<0.05)   in HBMVEC cells treated with lupus serum (Figure 6). 
Although treatment with C5a showed increase in gene expression levels of BAX, BCL2L11, 
APAF-1 and BIK, significant increase was observed in BAX (82%, p<0.01) and BCL2L11 
(80%, p<0.05) gene expression.  HBMVEC cells treated with normal serum were used as 
controls. However when HBMVEC were pretreated with the C5aRa and subsequently with 
lupus serum, BAX, BCL2L11, APAF-1 and BIK, gene expression was significantly 
decreased as compared to HBMVEC treated with lupus serum alone (72 % decrease p<0.01 
(BAX); 55% decrease p<0.01 (BCL2L11); 27% decrease  (NS) (APAF-1) and 62% decrease 
p<0.01 (BIK) respectively) indicating that C5a/C5aR1 signaling is an important aspect BBB 
integrity in lupus.  
Caspase 1 and Caspase 8 gene expression was significantly higher in cells treated 
with lupus serum compared to those treated with control serum (40 % increase in Caspase 1 
vs control, p<0.05) and 89% increase in Caspase 8 vs control p<0.001 respectively) (Figure 
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7).  No significant changes were observed in Caspase 4 and 10 gene expression, when treated 
with C5a or lupus serum. In HBMVEC pretreated with the C5aRa and subsequently with 
lupus serum, Caspase 8 gene expression  too was significantly decreased as compared to 
HBMVEC treated with lupus  serum alone  (29% decrease p<0.05) indicative of the 
involvement of C5a/C5aR1 signaling. 
HBMVEC cells treated with lupus serum, showed a significant  increase in the  gene 
expression levels of several cell death-inducing effector  proteins  such as FADD (48% 
increase, p<0.01); CIDEB (314% increase, p<0.001); DFFA (38% increase, p<0.05)  and 
DAPK1 (60%, increase p<0.01) respectively (Figure 8). Treatment with C5a too showed 
increase in FADD, CIDEB, DFFA and DAPK1 gene expression levels with significant 
increase in FADD (51%, p<0.01), CIDEB (94%, p<0.01) DFFA (58% increase, p<0.01) and 
DAPK1 (243%, increase p<0.001)  respectively.  Statistically control comparators were 
HBMVEC cells treated with normal serum.  In HBMVEC pretreated with the C5aRa and 
subsequently with lupus serum, FADD and CIDEB gene expression  was significantly 
decreased as compared to HBMVEC treated with lupus  serum alone  (22% decrease, p<0.05 
( FADD) and  80% decrease, P<0.001 (CIDEB) respectively)  indicative of the role of 
C5a/C5aR1 signaling in SLE.  
 
 
DISCUSSION 
Our earlier results demonstrate complement dependent loss of blood-brain barrier integrity in 
mouse brain in vivo and in brain endothelial cells in vitro (5, 6). Results of the present study 
suggest pathological vascular remodeling occurs in lupus resulting in the loss of BBB 
integrity. At 18 weeks of age there was a significant reduction in the number of brain 
vascular endothelial cells. Significant apoptosis was observed in the vascular endothelium 
Gene  Accession # Forward Reverse Amplicon length bp Tm
β -actin NM_001101.3 5’-TTCTACAATGAGCTGCGTGTG-3’ 5’-GGGGTGTTGAAGGTCTCAAA-3’ 114 58
BCL-2 L11 NM_001204106.1 5’-CTGCTGGACACACACATACA -3’ 5’-GGGCTGAGGAAACAGAGTAAA -3’ 135 58
BAX- BCL-2 associated X protein NM_000633.2 5'-TGG AGCTGCAGAGGATGATTG-3' 5'-GAAGTTGCCGTCAGAAAACATG- 
 
3' 121 60
BIK- BCL-2 interacting Killer ( apoptosis-inducing) NM_001197.4 5’-CTGGAACACTGCTGAGGTTT-3’ 5’-GACAATTGCAGAGCCATAGGA -3’ 100 62
DFFA-DNA fragmentation factor 45-kD  subunit A NM_004401.2 5’-CACCCTCAGCCTCATCATTT -3’ 5’-GCGTATGTTGAGACCTGGAATA -3’ 94 58
CIDEB cell death-inducing DFFA-like effector b XM_005267540.3 5’-CATCTCTGTCACGTCCACTAATC-3’ 5’-CTCACTGCTCTGGCTTCATT-3’ 104 62
FADD Fas associated via death domain NM_003824.3 5’-TCTCCTCTCTGAGACTGCTAAG -3’ 5’-AGAGAGTGCTGTGTGTCAATC-3’ 102 58
DAPK1 death-associated protein kinase 0 NM_001288729.0 5’-GTGGATGGTCATTGCAGTTTAAG-3’ 5’-TACTGGAGGATGAGAGATGGAG-3’ 109 58
APAF-1 Apototic protease  activating factor NM_001160.2 5’-GGACGACAGCCATTTCCTAATA-3’ 5’-GCAGCTTAGCTTGCTGATAAAC-3’ 82 58
CASP1 -caspase 1 NM_001223.4 5’-ACACAAGAAGGGAGGAGAGA-3’ 5’-CTTCACCCATGGAACGGATAA-3’ 84 60
CASP4- caspase 4 NM_001225.3 5’-GAATCTGACAGCCAGGGATATG-3’ 5’-CCATGAGACATGAGTACCAAGAA -3’ 102 60
CASP8- caspase 8 NM_001080124.1 5’-GGAGCTGCTCTTCCGAATTA -3’ 5’-CATGACCCTGTAGGCAGAAA-3’ 124 62
CASP10- caspase 10 NM_001206524.1 5’-ACAACTCTCCCTCCCAGATAA-3’ 5’-CTTAGTCTGTAAGTGAGTGGGC-3’ 112 58
 Table  1:  Primer sequences
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which could lead to the reduced cell number. In addition, our data show that these results are 
translatable, since human brain endothelial cells (HBMVEC) in culture, when exposed to 
lupus serum from patients underwent apoptosis.  
The pathology in CNS lupus includes both vascular and parenchymal damage. The 
parenchymal injury occurs only after the BBB is disrupted allowing the entry of antibodies, 
infiltrating cells and inflammatory mediators (66). In addition, breach of the BBB results in 
altered metabolic profiles (67). Our results are the first to show that pathologic remodeling 
occurred in brains of MRL/lpr mice indicating loss of endothelial cells that results in 
increased intercellular and transcellular transport across the BBB. This is in line with our 
earlier results where monolayer of bEnd3 cells (mouse brain endothelial cells) in culture was 
rendered leaky when treated with lupus serum.  
Several studies have shown that apoptosis occurs in lupus brains. Entry of a number of toxic 
effectors such as autoantibodies and other inflammatory mediators could cause cell apoptosis.   
One of the circulating proteins in lupus serum that correlate with CNS lupus is the 
complement protein C5a (30, 68-70). C5a was shown to cause apoptosis in different setting 
such as sepsis (71). Our studies have clearly demonstrated that C5a induces apoptosis in 
lupus brain, which was alleviated by inhibition of C5a/C5aR1 signaling (24). In addition, C5a 
induced apoptosis in bEnd3 cells (5, 35). Brain endothelial cells are susceptible to 
complement-mediated effects, due to their exposure to both systemic and CNS synthesized 
complement proteins. Complement-mediated endothelial damage promotes BBB breakdown, 
resulting in neuro-inflammation due to an influx of active complement fragments and 
cytokines. 
Our earlier studies using the human HBMVEC cells showed reduced TEER (transendothelial 
electrical resistance) when treated with lupus serum indicating reduced resistance to transport 
across the layer (62). In this study our results show that both lupus serum and C5a caused 
endothelial cell apoptosis in HBMVEC cells, which could be reduced by inhibition of 
C5a/C5aR1 signaling, indicating complement dependence. 
In non-immune cells such as endothelial cells, apoptosis signals may be initiated by both the 
intrinsic and extrinsic pathways. The intrinsic pathway, or the BCL-2 pathway, is induced by 
activation of caspase-9 via APAF-1 (Apoptotic protease activating factor) and cytochrome c 
causing rupture of the mitochondrial membrane, via the release of Bcl-2 family proteins into 
the cytoplasm (72).  Our results show a significant increase in APAF-1 gene expression in 
C5a and lupus treated HBMVEC We  also observed a significant increase in gene expression 
levels of BAX; (a BCL2 associated pro-apoptotic; BIK; (a apoptosis inducing protein) and 
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BCL-2L11 (apoptosis facilitator)  in  HBMVEC cells treated with lupus serum.  These 3 
BCL2 family members act as anti- or pro-apoptotic regulators that are involved in a wide 
variety of cellular activities. BAX forms a heterodimer with BCL2, and functions as an 
apoptotic activator and interacts with the mitochondrial voltage-dependent anion channel 
(VDAC), leading to the loss in membrane potential and the release of cytochrome c. 
BCL2L11 induces apoptosis via the cysteine-aspartic acid protease (caspase) dependent 
pathway. 
The extrinsic pathway, on the other hand, is caspase 8/10 dependent. Sequential activation of 
caspases plays a central role in the execution-phase of cell apoptosis (73). In our study, 
treatment with lupus serum resulted in increased gene expression of Caspase 1 and 8. 
Caspase 10 is suggested to be modulated by Caspase 8 and activates caspases 3 and 7 
resulting in cell apoptosis. We did not observe a significant change in Caspase 10 gene 
expression but observed activation of caspases 3 and 7. Increased caspase-1 in lupus treated 
HBMVEC can lead to activation of effector caspases resulting in endothelial cells apoptosis 
and decrease in BBB function. Casp-1 and Casp-10 are initiator caspases which cleave 
inactive pro-forms of effector caspases, thereby activating them, the effector caspases in turn 
cleave other protein substrates within the cell, to trigger the apoptotic process.  
In addition, our results show that treatment of HBMVEC with C5a and lupus serum resulted 
in a significant increase in gene expression of several cell death-inducing effector family 
proteins that include FADD, CIDEB, DAPK1, DFFA, and RIPK1, which was C5a/C5aR1 
signaling dependent. Fas-Associated Death Domain (FADD) is an adaptor molecule that is 
recruited by TNFRSF6/Fas-receptor, tumor necrosis factor receptor, TNFRSF25, and 
TNFSF10/TRAIL-receptor, to participate in the death signaling initiated by these receptors 
(74). DNA fragmentation factor (DFF), is the substrate for caspase-3 and triggers DNA 
fragmentation during apoptosis, while cell death-inducing DFFA-like effector (CIDE) 
proteins contribute to the chromatin condensation and DNA fragmentation events of 
apoptosis. The CIDE_N domain is believed to regulate the activity of ICAD/DFF45, and the 
CAD/DFF40 and CIDE nucleases during apoptosis (75). The extrinsic apoptotic pathway is 
activated by several extracellular ligands binding to cell-surface death receptors, which leads 
to the formation of the death-inducing signaling complex (DISC).  The increased expression, 
observed in this study, of FADD and the initiator caspases, 1 and 8 suggest that apoptosis 
may occur through the DISC complex and not through caspase 4 and 10, the expression of 
which remained unchanged in lupus.  
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In conclusion, our studies demonstrate for the first time that vascular remodeling with 
reduction in number of endothelial cells occurs in experimental lupus brain. Apoptosis plays 
a key role in this setting. Another important feature of this study is the demonstration that the 
results obtained in the mouse cells could be replicated in human vascular endothelial cells 
suggesting that the results could be translated to human settings. Lastly, our results show that 
the observed changes in brain vasculature are C5a/C5aR1 dependent, and therefore continue 
to strengthen the possibility that interrupting C5a/C5aR1 signaling could be an effective 
therapeutic target for CNS lupus and other neurodegenerative diseases. 
Legends: 
Fig 1: Vascular damage occurs in experimental lupus brain.  Representative scanning 
electron microscopy images of brain vasculature casts show endothelial cell irregularities in 
MRL/lpr mice (CD) compared to congenic MRL+/+ controls (AB). The endothelial cell 
number was quantitated using Image J (E). Endothelial cell number was significantly reduced 
in lupus mice as shown in (E). BA, Basilar artery; ACA, Anterior cerebral artery; MCA, 
middle cerebral artery; PCA, Posterior cerebral artery. Statistical analysis showed significant 
change, p<0.05. 
Figure 2: Endothelial cell viability is reduced in experimental lupus. HBMVEC cells 
treated with lupus serum, showed a significant decrease in cell viability as measured by an 
MTT assay. Treatment of lupus treated cells with C5aRa reversed the lupus induced effect 
indicating that the lupus induced effects are mediated via C5a/C5aR1 signaling. Results are 
expressed as the mean ± SD from n=3 separate experiments. p<0.05 is considered statistically 
significant. 
 
Fig 3: Endothelial cells in brain vasculature undergo apoptosis in experimental lupus. 
MRL+/+ mice and MRL/lpr mice were euthanized at 18 wk of age. Brains were harvested, 
cryosectioned, immunostained, and observed using a Zeiss confocal microscope. 
Representative sections were stained with Alexa 594 labeled anti-caspase-3 and observed at 
×60 under oil. Lining of the vasculature was stained using Alexa 488 labeled agglutinin1. 
Overlay (C) shows increased caspase3 activity in the brain vasculature of MRL/lpr mouse 
brain (B) compared to controls (A). 
 
 Figure 4: C5a induced endothelial cell apoptosis occurs through Caspases 3 and 7 
pathway. Representative images shown were stained with CellEvent® Caspase-3/7 Green 
Detection Reagent with an absorption/emission maxima of ~502/530 nm. The representative 
histogram shows the Image J quantitation (e) of fluorescence signal intensity in pixel units 
with significant increase in C5a, and lupus serum treated HBMVEC cells as compared to the 
normal controls. C5aRa treatment reduced caspase3/7 activation in lupus serum treated 
HBMVEC cells. Imaging was performed with the EVOS® FL Cell Imaging System. 
 
Figure 5: TUNEL staining reveals that C5a induces endothelial cells apoptosis in lupus 
brain 
DNA fragmentation was detected using a TUNEL Apo-Green Detection Kit. The number of 
TUNEL-positive cells were quantified in 10 representative fields. The results are presented as 
a representation of three separate experiments and the histogram shows the Image J 
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quantitation of fluorescence signal intensity in pixel units. Increased TUNEL staining is 
observed in HBMVEC cells treated with lupus serum or C5a compared to controls, which 
was reduced by treatment with C5aRa. Imaging was performed with the EVOS® FL Cell 
Imaging System. 
  
Figure 6: Gene expression of apoptotic regulatory proteins are C5a dependent in lupus. 
Effect of C5a, C5aRa and/or lupus serum on gene expression of pro-apoptotic regulatory 
proteins a) BAX; b) BCL-2L11; c) APAF-1 and d) BIK were assessed. RNA was extracted 
from HBMVEC cells and subjected to real time-PCR. Expression levels of BAX, BCL-2L11, 
APAF-1 and BIK genes were significantly increased in lupus serum treated cells compared to 
control, while C5aRa treatment alleviated the change. Results are expressed as the Mean ± 
SD, n=3 separate experiments. p<0.05 is considered statistically significant. 
  
Figure 7: C5a/C5aR1 signaling causes endothelial cell apoptosis through caspase 1/8 
pathway. Expression of a) Casp-1; b) Casp-8; c) Casp-4 and d) Casp-10 were assessed in 
HBMVEC cells treated with C5a, lupus serum alone and in combination with C5aRa. 
Treatment with lupus serum significantly increased Casp-1 and Casp-8 gene expression 
levels in HBMVEC cells, while no significant differences were observed in Casp-4 and Casp-
10 gene expression levels. All statistical comparisons were made to the untreated controls. 
Results are expressed as the Mean ± SD from n=3 separate experiments. p<0.05 is considered 
statistically significant. 
  
Figure 8: Apoptotic biomarker gene expression is C5a/C5aR1 dependent in CNS lupus. 
Gene expression of apoptotic biomarkers a) FADD; b) CIDEB; c) DFFA and d) DAPK1 was 
determined in HBMVEC cells were treated with C5a or lupus serum. The gene expression 
levels of FADD; CIDEB; DFFA and DAPK1 were measured using real time-PCR. C5a and 
lupus serum treatment significantly increased FADD; CIDEB; DFFA and DAPK1 gene 
expression levels. Treatment with C5aRa resulted a reversal on the lupus mediated 
effects. All statistical comparisons were made to the untreated controls. Results are expressed 
as the Mean ± SD from n=3 separate experiments. p<0.05 is considered statistically 
significant. 
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